Join to access to all OVN content. Join for Free
Repackage what you have for what you want
MSL career transition MSL capability continuum post-pandemic MSL landscape MSL digital proficiency MSL certification programs

Repackage what you have for what you want


Share This Article


Summary

In this episode, Cherie Hyder shares her journey from the FDA to the industry, discussing the transition and how to enhance skills for a successful MSL career. She emphasizes the importance of documenting experience and understanding the MSL role, highlighting the MSL capability continuum and certification programs. Cherie discusses the significance of soft skills and digital proficiency, along with predictions for the post-pandemic MSL landscape. She offers insights into effective email communication, evolving metrics, and the critical role of insight gathering. The episode wraps up with best practices for post-meeting note-taking and career development strategies.

Check out my latest podcast with Cherie Hyder, Medical Excellence at Biohaven who discusses how to repackage what you have for what you want.

Cherie shares…. 

 How to position yourself for MSL roles

 Tool and resources to be aware of

 How to showcase important skills and traits

 Certification programs and if they are worth it

 Mandatory skills for the MSL of the future

Click for Source
MSL career transition, MSL capability continuum, post-pandemic MSL landscape, MSL digital proficiency, MSL certification programs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Mastering the Medical Affairs Professional Role: Inside and Out
Partner Avatar MSL Talk: Tom Caravela, Kent Christofferson

Mastering the Medical Affairs Professional Role: Inside and Out

Podcast
Landing My First MSL Role: From the Inside
Partner Avatar MSL Talk: Tom Caravela, Amanda Vaughn

Landing My First MSL Role: From the Inside

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
OVN Avatar Karen Geary

Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?

Explore OVN